Published in Metabolism on August 01, 2005
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc (2009) 1.24
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J (2009) 0.85
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag (2010) 0.83
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine (2006) 0.82
Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis (2011) 0.81
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment. Diabetes (2009) 0.80
The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica (Cairo) (2012) 0.79
Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag (2007) 0.77
Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des (2011) 4.16
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin (2002) 3.12
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother (2012) 2.01
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Time for new indications for statins? Med Sci Monit (2009) 1.87
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care (2002) 1.73
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. J Psychosom Res (2010) 1.54
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin (2011) 1.53
The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol (2013) 1.53
Comparison of the five 2011 guidelines for the treatment of carotid stenosis. J Vasc Surg (2012) 1.51
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Atorvastatin: safety and tolerability. Expert Opin Drug Saf (2010) 1.47
Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis? Angiology (2009) 1.47
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
The role of Toll-like receptors in renal diseases. Nat Rev Nephrol (2010) 1.42
Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology (2012) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. Ann Hematol (2004) 1.39
Optimal statin type and dosage for vascular patients. J Vasc Surg (2011) 1.39
Multiple actions of high-density lipoprotein. Curr Opin Cardiol (2008) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
CORONA, statins, and heart failure: who lost the crown? Angiology (2008) 1.38
Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg (2007) 1.38
Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors? Ann Allergy Asthma Immunol (2007) 1.38
Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer (2007) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Adrenal incidentaloma: a diagnostic challenge. Hormones (Athens) (2009) 1.29
Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol (2011) 1.27
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.27
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol (2008) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
The prevalence of metabolic syndrome in various populations. Am J Med Sci (2007) 1.19
Epidemiological survey for the prevalence of overweight and abdominal obesity in Greek adolescents. Obesity (Silver Spring) (2008) 1.19
Drug-induced fibrotic valvular heart disease. Lancet (2009) 1.19
Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. J Diabetes Complications (2008) 1.14
Response to 'Red blood cell distribution width is a predictor of readmission in cardiac patients'. Clin Cardiol (2013) 1.14
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
Postoperative atrial fibrillation - what do we really know? Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int (2011) 1.12
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Vascular risk factors in South Asians. Int J Cardiol (2008) 1.11
Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther (2014) 1.11
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (2010) 1.10
HSP 70 and atherosclerosis--protector or activator? Expert Opin Ther Targets (2009) 1.10
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int (2011) 1.10
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol (2007) 1.09
Lone atrial fibrillation: what do we know? Heart (2009) 1.08
Clinical relevance of postprandial lipaemia. Curr Med Chem (2005) 1.08